Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011057 | 1.00 | GPR119 (0.51) | GPR119POLBCCNA2CDK2GRM5 | |
| SCHEMBL2792027 | 0.88 | GPR119 (0.43) | GPR119POLBGRM5HPGDS | |
| SCHEMBL2792024 | 0.88 | GPR119 (0.43) | GPR119POLBGRM5HPGDS | |
| SCHEMBL1199881 | 0.83 | GPR119 (0.58) | GPR119POLBGRM5HPGDS | |
| SCHEMBL23858285 | 0.83 | PIK3CD (0.38) | GRM5 | |
| SCHEMBL20839829 | 0.81 | GPR119 (0.44) | GPR119 | |
| SCHEMBL31605050 | 0.81 | STS (0.42) | GPR119 | |
| SCHEMBL25258371 | 0.81 | GPR119 (0.44) | GPR119POLB | |
| SCHEMBL29774310 | 0.81 | GPR119 (0.44) | GPR119 | |
| SCHEMBL6356443 | 0.81 | GPR119 (0.56) | GPR119POLBCCNA2CDK2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-21 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| EP-4126840-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115362151-A | Aryl piperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20220363679-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | US | disclosed |
| WO-2021191384-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191384-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | GPR119 119/4885POLB 643/4885CCNA2 3524/4885 |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | GPR119 119/4885POLB 643/4885CCNA2 3524/4885 |
| US-20220363679-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | GPR119 119/4885POLB 643/4885CCNA2 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.